Time to first sustained improvement in QUALMS Total
Figure 4. · Panel A
Panel A 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Mikkael A Sekeres, Amer M Zeidan, Valeria Santini, Rami S Komrokji, Pierre Fenaux, Michael R Savona, Yazan F Madanat, David Valcárcel, Antoine Regnault, Kristin Creel, Libo Sun, Ying Wan, Shyamala Navada, Tymara Berry, Faye Feller, Uwe Platzbecker, María Díez-Campelo, Esther Natalie Oliva
Haematologica 111(7) 2385-2396
Red blood cell (RBC) transfusions for anemia associated with lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) often contribute to reduced quality of life (QOL). Thus, reduction in RBC transfusion dependency (TD) is a primary therapeutic goal. Imetelstat is a first-in-class, competitive telomerase inhibitor approved to treat certain adult patients with LRMDS with RBC-TD anemia who have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents. In the phase III IMerge study (clinicaltrials.gov identifier: NCT02598661), treatment with imetelstat resulted in clinically meaningful, statistically significant increases in the primary endpoint of ≥8-week RBC transfusion independence (TI) versus placebo. Because patients with LR-MDS experience detrimental effects on numerous facets of QOL (physical, emotional, social, and functional), these exploratory analyses assessed patient-reported outcomes using the Functional Assessment of Chronic Illness Therapy-Fatigue, Quality of Life in Myelodysplasia Scale, and Functional Assessment of Cancer Therapy-Anemia questionnaires as part of the phase III IMerge study. Nominal P values were reported. Fewer imetelstat-treated patients experienced deterioration in fatigue levels and more imetelstat-treated patients experienced sustained improvement in fatigue levels and QOL versus placebo. In the imetelstat group, 8-week, 24-week, and 1-year RBC-TI responders had sustained improvements in predefined significance thresholds versus non-responders for fatigue (70%, 73%, and 88%, respectively, vs. 37%, 41%, and 44%, respectively; P<0.001, P=0.004, and P=0.002) and QOL across different measures of response (43-53% vs. 21-30%; P≤0.0126). These results suggest that treatment with imetelstat may be associated with improvement in QOL beyond fatigue while sustaining RBC-TI in patients with LR-MDS with RBC-TD anemia.
1 个 Figure · 3 个 KM 面板
Time to first sustained improvement a in QUALMS scores (patient-reported outcomes population). QUALMS Total (A), QUALMS-P (B), and QUALMS-E (C). Sustained meaningful improvement was defined for QUALMS as ≥9-, ≥8-, or ≥9-point increase for ≥2 consecutive assessments in QUALMS Total, QUALMS-P, and QUALMS-E scores, respectively. 35 NE: not estimable; QUALMS: Quality of Life in Myelodysplasia Scale; QUALMS-E: Quality of Life in Myelodysplasia Scale - emotional burden; QUALMS-P: Quality of Life in Myelodysplasia Scale - physical burden.
Figure 4. · Panel A
Panel A 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4. · Panel B
Panel B 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4. · Panel C
Panel C 是同一 Figure 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。